Compare MOGU & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MOGU | DARE |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.3M | 13.9M |
| IPO Year | 2018 | 2014 |
| Metric | MOGU | DARE |
|---|---|---|
| Price | $1.88 | $0.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 1.9K | ★ 827.9K |
| Earning Date | 01-29-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,807,885.00 |
| Revenue This Year | N/A | $2,115.12 |
| Revenue Next Year | N/A | $122.62 |
| P/E Ratio | $13.81 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.27 | $0.69 |
| 52 Week High | $5.50 | $3.78 |
| Indicator | MOGU | DARE |
|---|---|---|
| Relative Strength Index (RSI) | 44.07 | 26.95 |
| Support Level | $1.84 | N/A |
| Resistance Level | $2.12 | $2.21 |
| Average True Range (ATR) | 0.04 | 0.06 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 26.32 | 12.71 |
MOGU Inc is an online service provider in China, operating a KOL-driven online fashion and lifestyle platform, Mogujie, and providing customized online branding solutions to businesses. The company, on its platform, provides content related to fashion and lifestyle guides in various multimedia formats, which include Live Video Broadcasts, Short-form Videos, Photography, and an Online Review Community. The company derives revenues from within China. It also provides online marketing, commission, financing, technology, and other relevant services to merchants and users, as well as technology services to brand owners.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.